Angiographic maximal luminal diameter and appropriate deployment of the everolimus-eluting bioresorbable vascular scaffold as assessed by optical coherence tomography: an ABSORB cohort B trial sub-study

Josep Gomez Lara, Roberto Diletti, S Brugaletta, Yoshinobu Onuma, V Farooq, L Thuesen, D McClean, J Koolen, JA Ormiston, S Windecker, R Whitbourn, D Dudek, C Dorange, S Veldhof, R Rapoza, Evelyn Regar, Hector Garcia Garcia, PWJC (Patrick) Serruys

Research output: Contribution to journalArticleAcademicpeer-review

54 Citations (Scopus)


Aims: Bioresorbable vascular scaffolds (BVS) present different mechanical properties as compared to metallic platform sterns. Therefore, the standard procedural technique to achieve appropriate deployment may differ. Methods and results: Fifty-two lesions treated with a 3x18 mm BVS were imaged with optical coherence tomography (OCT) post-implantation and screened for parameters suggesting non-optimal deployment. These included minimal scaffold area (rninSA)<5 mm(2), residual area stenosis (RAS)>20%, edge dissections, incomplete scaffold/strut apposition (ISA)>5% and scaffold pattern irregularities. The angiographic proximal and distal maximal lumen diameters (DMAX) were measured by quantitative coronary angi Conclusions: BVS implantation guided with quantitative angiography may improve the OCT findings of optimal deployment. The clinical significance of these angiographic and OCT findings warranted long term follow-up of larger cohort of patients.
Original languageUndefined/Unknown
Pages (from-to)214-224
Number of pages11
Issue number2
Publication statusPublished - 2012

Research programs

  • EMC COEUR-09

Cite this